rolipram has been researched along with Bone Cancer in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Guo, CH | 1 |
Bai, L | 1 |
Wu, HH | 1 |
Yang, J | 1 |
Cai, GH | 1 |
Wang, X | 1 |
Wu, SX | 1 |
Ma, W | 1 |
Narita, M | 1 |
Murata, T | 1 |
Shimizu, K | 1 |
Sugiyama, T | 1 |
Nakagawa, T | 1 |
Manganiello, VC | 1 |
Tagawa, T | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy[NCT04631471] | Phase 3 | 400 participants (Anticipated) | Interventional | 2021-12-22 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
2 other studies available for rolipram and Bone Cancer
Article | Year |
---|---|
The analgesic effect of rolipram is associated with the inhibition of the activation of the spinal astrocytic JNK/CCL2 pathway in bone cancer pain.
Topics: Analgesics; Animals; Anthracenes; Astrocytes; Bone Neoplasms; Cancer Pain; Chemokine CCL2; Cyclic Nu | 2016 |
Phosphodiesterase 4 in osteoblastic osteosarcoma cells as a potential target for growth inhibition.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Antineoplastic Agents; Bone Neoplasms; Cell Division; Cell Line | 2003 |